Tirzepatide vs Retatrutide
Tirzepatide and retatrutide are closely related synthetic peptides used in laboratory research on incretin and glucagon receptor signaling. Both are 39-amino-acid peptides that carry a C20 fatty diacid moiety for albumin binding, and their reported half-lives are similar. The defining difference is receptor coverage: tirzepatide is a dual agonist of the GIP and GLP-1 receptors, while retatrutide is a single-peptide triple agonist that adds activity at the glucagon receptor (GCGR).
That third receptor changes the questions each compound can answer. A study of how GIP and GLP-1 receptor signaling combine is naturally built around tirzepatide. A study asking what glucagon receptor engagement contributes on top of that incretin pair needs retatrutide, usually with tirzepatide alongside it as the dual-agonist reference. This page compares the two on structure, receptor pharmacology and laboratory handling, using published molecular and pharmacological data only.
In this catalog tirzepatide is listed as GLP-2 TZ (tirzepatide) and retatrutide as GLP-3 RT (retatrutide). Both are supplied as lyophilized powder strictly for in-vitro laboratory research and are not for human or animal consumption.
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP receptor and GLP-1 receptor | GIP, GLP-1 and glucagon (GCGR) receptors |
| Class | Dual GIP/GLP-1 receptor agonist, described as "imbalanced" | Single-peptide triple receptor agonist |
| Peptide basis | GIP sequence; Aib at positions 2 and 13; C-terminal amide | Engineered single peptide with activity at all three receptors |
| Length | 39 amino acids, linear | 39 amino acids |
| Fatty-acid moiety | C20 fatty diacid through a linker (albumin binding) | C20 fatty diacid (albumin binding) |
| Molecular formula | C225H348N48O68 | C221H342N46O68 |
| Molecular weight | About 4813.5 Da | About 4731.4 Da |
| Half-life (pharmacokinetic property) | About 5 days | About 6 days |
| Supplied form in this store | GLP-2 TZ: lyophilized powder, 10mg and 20mg vials | GLP-3 RT: lyophilized powder, 10mg and 20mg vials |
About Tirzepatide
Tirzepatide is a 39-amino-acid linear peptide built on the GIP sequence and engineered to act at both the GIP receptor and the GLP-1 receptor. It carries Aib (alpha-aminoisobutyric acid) at positions 2 and 13, the first of which protects the N-terminus from DPP-4 cleavage. The C-terminus is amidated, and a C20 fatty diacid moiety attached through a linker allows reversible binding to serum albumin. Albumin binding underlies its reported half-life of about 5 days, a pharmacokinetic property of the molecule.
Tirzepatide is usually described as an "imbalanced" agonist. Its affinity for the GIP receptor is comparable to native GIP, while its affinity for the GLP-1 receptor is weaker than native GLP-1. At the GLP-1 receptor it also favors cAMP signaling over beta-arrestin recruitment, a form of biased agonism. In cell and animal models it has been used to study glucose-dependent insulin secretion, incretin signaling, gastric emptying and appetite-related signaling pathways.
Tirzepatide has been studied extensively in published literature, including clinical research; a PubMed search for tirzepatide is a practical entry point. For a fuller review, read the tirzepatide research overview, and for preparing 10mg and 20mg vials see the tirzepatide reconstitution guide.
About Retatrutide
Retatrutide is a single 39-amino-acid peptide designed to activate three receptors: the GIP receptor, the GLP-1 receptor and the glucagon receptor (GCGR). Like tirzepatide, it carries a C20 fatty diacid moiety that binds serum albumin, and its reported half-life is about 6 days, close to that of tirzepatide.
Its potency profile differs from tirzepatide's in an informative way. Retatrutide is reported to be more potent than native GIP at the GIP receptor, and less potent than the native ligands at the GLP-1 and glucagon receptors. Glucagon receptor signaling is linked in cell and animal models to energy expenditure and hepatic metabolism, so retatrutide brings those pathways into the same experiment as incretin signaling. Pathways examined with retatrutide in cell and animal models include:
- Glucose-dependent insulin secretion and incretin signaling, shared with tirzepatide
- Energy expenditure pathways linked to glucagon receptor activation
- Hepatic metabolism, including glucagon receptor signaling in liver cell models
- Gastric emptying and appetite-related signaling pathways
Because one molecule engages all three receptors, study designs need controls that can separate a glucagon receptor contribution from GIP and GLP-1 receptor activity. Retatrutide's published literature, which includes clinical research, is smaller than tirzepatide's; a PubMed search for retatrutide lists it. See the retatrutide research overview and the retatrutide reconstitution guide for 10mg and 20mg vials.
Which Should Researchers Choose?
- Dual incretin agonism: studies of how GIP and GLP-1 receptor signaling combine, without a glucagon receptor component, are built around tirzepatide.
- Glucagon receptor contribution: studies asking what GCGR activation adds to incretin signaling call for retatrutide, with tirzepatide as the dual-agonist comparator.
- Relative receptor potency: concentration-response experiments in GIP, GLP-1 and glucagon receptor-expressing cell lines can contrast an imbalanced dual agonist with a triple agonist that exceeds native GIP potency at the GIP receptor.
- GLP-1 receptor signaling bias: tirzepatide's preference for cAMP signaling over beta-arrestin recruitment makes it a well-characterized reference for biased agonism assays.
- Energy expenditure and hepatic metabolism models: retatrutide is the relevant compound when glucagon receptor-linked pathways are part of the hypothesis.
- Matched structural pair: with the same length, a C20 fatty diacid on each and similar half-lives, the two pair well when receptor coverage is the variable being isolated.
For a single-receptor reference point, see semaglutide vs tirzepatide and semaglutide vs retatrutide, or see all three receptor profiles side by side in the three-way comparison.
Frequently Asked Questions
What is the main difference between tirzepatide and retatrutide?
Receptor coverage. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors; retatrutide is a single-peptide triple agonist that also activates the glucagon receptor (GCGR). Structurally they are close: both are 39 amino acids long and both carry a C20 fatty diacid moiety for albumin binding.
What does "triple agonist" mean?
It means one molecule binds and activates three distinct receptors, rather than a mixture of separate peptides each acting at one receptor. The balance between the three receptor activities is fixed by the molecule's design, which suits studies that need all three pathways engaged together but limits studies that vary each receptor's contribution independently.
Is retatrutide simply a stronger version of tirzepatide?
No single scale captures the difference. Potency differs receptor by receptor: retatrutide is reported to be more potent than native GIP at the GIP receptor and less potent than the native ligands at the GLP-1 and glucagon receptors, while tirzepatide's GIP receptor affinity is comparable to native GIP and its GLP-1 receptor affinity is weaker than native GLP-1. They are different research tools rather than ranked versions of one compound.
How are the lyophilized vials stored and reconstituted?
Both compounds are handled the same way. Lyophilized vials are stored cold at 2-8 °C, or at -20 °C for long-term storage, and protected from light. They are reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water). The reconstituted solution is kept refrigerated at 2-8 °C, is not shaken, and is not frozen and thawed repeatedly. The reconstitution guides linked above cover each vial size.
Are these approved for human use?
No. The research-grade tirzepatide and retatrutide sold here are not approved for human use and are not for human or animal consumption. They are supplied strictly for in-vitro laboratory research, they are not medicines, and they are not equivalent to any approved pharmaceutical product.
How are these listed in the catalog?
Tirzepatide is listed as GLP-2 TZ and retatrutide as GLP-3 RT, each in 10mg and 20mg vials, with bacteriostatic water sold separately in 3 mL and 10 mL vials. Identity and purity for every batch are verified by HPLC and mass spectrometry, and each batch Certificate of Analysis is published on the COA page.
Shop these products
- Ships the same business day
- Free US shipping on $199+
- 14-day money-back guarantee